Indication
Plaque Psoriasis
15 clinical trials
20 products
2 drugs
Product
MSB11022Product
Humira®Clinical trial
A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque PsoriasisStatus: Completed, Estimated PCD: 2016-12-31
Product
CertolizumabClinical trial
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled (12-17 Years) Including a Single Open-Label Arm (6-11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis (PSO)Status: Recruiting, Estimated PCD: 2029-09-18
Product
PlaceboProduct
608Clinical trial
A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque PsoriasisStatus: Not yet recruiting, Estimated PCD: 2025-01-30
Clinical trial
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque PsoriasisStatus: Not yet recruiting, Estimated PCD: 2028-11-01
Product
DeucravacitinibClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy And Safety of SCD-044 in the Treatment of Moderate to Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2024-08-01
Product
SCD-044Clinical trial
A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque PsoriasisStatus: Completed, Estimated PCD: 2019-02-07
Product
BimekizumabClinical trial
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ICP-488 in Patients With Moderate to Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2024-10-08
Product
ICP-488Product
AdalimumabProduct
Certolizumab pegolClinical trial
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2018-08-14
Product
KHK4827Product
bimekizumabClinical trial
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2022-09-05
Product
608 Q2WProduct
StelaraProduct
SB17Clinical trial
A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (Proposed Ustekinumab Biosimilar) Compared to Stelara® in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2022-02-24
Product
TLL018Clinical trial
A Phase Ⅰb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of TLL-018 in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2023-08-30
Product
NDI-034858Clinical trial
A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Moderate to Severe Plaque PsoriasisStatus: Completed, Estimated PCD: 2022-08-19
Clinical trial
A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira® Pre Filled Syringe (40 mg) Continuously and Subjects Undergoing Repeated Switches Between Humira® Pre Filled Syringe (40 mg) and Hulio Pre-filled Syringe (40 mg)Status: Completed, Estimated PCD: 2023-09-06
Product
HumiraProduct
HulioClinical trial
A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque PsoriasisStatus: Active (not recruiting), Estimated PCD: 2025-03-19
Clinical trial
A Multicenter, Randomized, Parallel-Group, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2028-08-21
Drug
ustekinumabDrug
Varlilumab